171 related articles for article (PubMed ID: 30074466)
1. Clinical and biological significance of adamantinomatous craniopharyngioma with CTNNB1 mutation.
Hara T; Akutsu H; Takano S; Kino H; Ishikawa E; Tanaka S; Miyamoto H; Sakamoto N; Hattori K; Sakata-Yanagimoto M; Chiba S; Hiyama T; Masumoto T; Matsumura A
J Neurosurg; 2018 Aug; 131(1):217-226. PubMed ID: 30074466
[TBL] [Abstract][Full Text] [Related]
2. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
[TBL] [Abstract][Full Text] [Related]
3. Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche?
Hölsken A; Stache C; Schlaffer SM; Flitsch J; Fahlbusch R; Buchfelder M; Buslei R
Pituitary; 2014 Dec; 17(6):546-56. PubMed ID: 24356780
[TBL] [Abstract][Full Text] [Related]
4. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
[No Abstract] [Full Text] [Related]
5. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
6. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
Hölsken A; Kreutzer J; Hofmann BM; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Brain Pathol; 2009 Jul; 19(3):357-64. PubMed ID: 18540944
[TBL] [Abstract][Full Text] [Related]
7. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
[TBL] [Abstract][Full Text] [Related]
9. Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma.
Schlaffer SM; Buchfelder M; Stoehr R; Buslei R; Hölsken A
Front Genet; 2018; 9():49. PubMed ID: 29520296
[TBL] [Abstract][Full Text] [Related]
10. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
[TBL] [Abstract][Full Text] [Related]
11. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling.
Hölsken A; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Acta Neuropathol; 2010 May; 119(5):631-9. PubMed ID: 20131060
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
[TBL] [Abstract][Full Text] [Related]
13. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
14. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
[TBL] [Abstract][Full Text] [Related]
15. CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas.
Campanini ML; Colli LM; Paixao BM; Cabral TP; Amaral FC; Machado HR; Neder LS; Saggioro F; Moreira AC; Antonini SR; de Castro M
Horm Cancer; 2010 Aug; 1(4):187-96. PubMed ID: 21761366
[TBL] [Abstract][Full Text] [Related]
16. Can recurrences be predicted in craniopharyngiomas? β-catenin coexisting with stem cells markers and p-ATM in a clinicopathologic study of 45cases.
Guadagno E; de Divitiis O; Solari D; Borrelli G; Bracale UM; Di Somma A; Cappabianca P; Del Basso De Caro M
J Exp Clin Cancer Res; 2017 Jul; 36(1):95. PubMed ID: 28709442
[TBL] [Abstract][Full Text] [Related]
17. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
[TBL] [Abstract][Full Text] [Related]
18. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
[TBL] [Abstract][Full Text] [Related]
19. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
[TBL] [Abstract][Full Text] [Related]
20. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
[No Abstract] [Full Text] [Related]
[Next] [New Search]